SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details) - USD ($)	1 Months Ended			12 Months Ended
	Sep. 30, 2022	Dec. 31, 2020	Jul. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Product Revenue [Abstract]
Term over which revenue will be recognized				1 year
Government Grant Income [Abstract]
Product sales				$ 49,521,923	$ 47,818,452
Deferred revenue				0	0
POC Syphilis Diagnostic Test [Member]
Government Grant Income [Abstract]
Maximum amount of development agreement	$ 3,200,000
SARS-CoV-2 Ag System [Member]
Government Grant Income [Abstract]
Maximum amount of development agreement			$ 600,000
Multiplex DPP Respiratory Antigen Panel Point-of-care Test system [Member]
Government Grant Income [Abstract]
Maximum amount of development agreement		$ 12,700,000
Government Grant Income [Member]
Government Grant Income [Abstract]
Product sales				1,182,023	10,891,726
Government Grant Income [Member] | POC Syphilis Diagnostic Test [Member]
Government Grant Income [Abstract]
Product sales				600,000
Government Grant Income [Member] | SARS-CoV-2 Ag System [Member]
Government Grant Income [Abstract]
Product sales				0	200,000
Remainder amount to be recognized subject to obtaining EUA				200,000
Government Grant Income [Member] | Multiplex DPP Respiratory Antigen Panel Point-of-care Test system [Member]
Government Grant Income [Abstract]
Product sales				0	$ 10,900,000
Revenue recognized under agreement				$ 12,500,000
Minimum [Member]
Product Revenue [Abstract]
Revenue, payment terms				30 days
Maximum [Member]
Product Revenue [Abstract]
Revenue, payment terms				60 days